Objective: To evaluate the efficacy and user satisfaction of the MAIA™ telemedicine platform for postoperative telemonitoring and telerehabilitation in patients undergoing robot-assisted radical prostatectomy (RARP). Methods: Patients undergoing RARP (from April 2022 to January 2023) were divided into Group A, following the standard rehabilitation protocol, and Group B using the MAIA™ platform for the first 30-day post-intervention period. Perioperative, pathological, and functional variables (continence and potency rates, assessed via validated questionnaires) were collected and telerehabilitation protocol's adherence was monitored. The telerehabilitation system included an online platform for medical providers and a patient application, facilitating data acquisition, management, treatment planning, and monitoring. Patient and provider satisfaction were evaluated using the visual analogue scale score and validated telemedicine satisfaction questionnaire. Results: Totally, 227 patients were enrolled. No differences in perioperative or pathological variables were found. Group B had higher potency recovery rates than Group A (p=0.031); the potency recovery rates at 1 month and 3 months for Group B were 45% and 57%, respectively, and in Group A were 34% and 48%, respectively. At the multivariate analysis, MAIA™ use and the nerve-sparing (NS) were independent predictors of erectile function at both 1 month (MAIA™ use: odd ratio [OR] 2.03, 95% confidence interval [CI] 1.13–3.63, p=0.018; NS: OR 2.08, 95% CI 1.06–4.12, p=0.034) and 3 months (MAIA™ use: OR 1.89, 95% CI 1.07–3.34, p=0.028; NS: OR 1.90; 95% CI 1.02–3.54, p=0.044). Adherence monitoring revealed 4.6% of patients in Group B reported exercise issues due to pelvic pain onset and 10% did not take oral phosphodiesterase 5-inhibitors due to myalgia. All those patients restarted the rehabilitation program after televisit to address the causing problem, allowing restarting of a rehabilitation program. Patients reported high satisfaction with the MAIA™ platform use (mean visual analogue scale score: 88.7). Conclusion: The MAIA™ telemedicine platform seems to have a role in optimizing early potency recovery after RARP. Patient and provider satisfaction levels were high, emphasizing the user-friendliness of the platform.
Enhancing postoperative functional recovery: Impact of the MAIA™ telerehabilitation platform in robot-assisted radical prostatectomy patients
Amparore D.;De Cillis S.;Piramide F.;Checcucci E.;Cisero E.;Pini F.;Manfredi M.;Fiori C.;Porpiglia F.
2025-01-01
Abstract
Objective: To evaluate the efficacy and user satisfaction of the MAIA™ telemedicine platform for postoperative telemonitoring and telerehabilitation in patients undergoing robot-assisted radical prostatectomy (RARP). Methods: Patients undergoing RARP (from April 2022 to January 2023) were divided into Group A, following the standard rehabilitation protocol, and Group B using the MAIA™ platform for the first 30-day post-intervention period. Perioperative, pathological, and functional variables (continence and potency rates, assessed via validated questionnaires) were collected and telerehabilitation protocol's adherence was monitored. The telerehabilitation system included an online platform for medical providers and a patient application, facilitating data acquisition, management, treatment planning, and monitoring. Patient and provider satisfaction were evaluated using the visual analogue scale score and validated telemedicine satisfaction questionnaire. Results: Totally, 227 patients were enrolled. No differences in perioperative or pathological variables were found. Group B had higher potency recovery rates than Group A (p=0.031); the potency recovery rates at 1 month and 3 months for Group B were 45% and 57%, respectively, and in Group A were 34% and 48%, respectively. At the multivariate analysis, MAIA™ use and the nerve-sparing (NS) were independent predictors of erectile function at both 1 month (MAIA™ use: odd ratio [OR] 2.03, 95% confidence interval [CI] 1.13–3.63, p=0.018; NS: OR 2.08, 95% CI 1.06–4.12, p=0.034) and 3 months (MAIA™ use: OR 1.89, 95% CI 1.07–3.34, p=0.028; NS: OR 1.90; 95% CI 1.02–3.54, p=0.044). Adherence monitoring revealed 4.6% of patients in Group B reported exercise issues due to pelvic pain onset and 10% did not take oral phosphodiesterase 5-inhibitors due to myalgia. All those patients restarted the rehabilitation program after televisit to address the causing problem, allowing restarting of a rehabilitation program. Patients reported high satisfaction with the MAIA™ platform use (mean visual analogue scale score: 88.7). Conclusion: The MAIA™ telemedicine platform seems to have a role in optimizing early potency recovery after RARP. Patient and provider satisfaction levels were high, emphasizing the user-friendliness of the platform.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
